Portal Therapeutics webinar
June 23
On Tuesday, June 23, Portal Therapeutics (a @GondolaBio affiliate company) is hosting an in-depth webinar reviewing the Phase 2a GATEWAY study data for PORT-77 in erythropoietic protoporphyria (EPP).
For clinicians managing rare porphyrias, this session will offer valuable insights into:
- The latest clinical safety and efficacy data.
- PORT-77’s mechanism of action.
- Upcoming clinical development pathways for both EPP and X-linked protoporphyria (XLP).
Don’t miss the opportunity to engage with the team behind the data and discuss the future landscape of EPP management.
Secure your spot here: https://gondolabio.zoom.us/webinar/register/WN_q99sTmgZSYaoC3My4GTeeQ
PORT-77 is an investigational agent and has not been approved by any global health authorities.